Ken Griffin Relmada Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 43,000 shares of RLMD stock, worth $149,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,000

Previous 39,700 8.31%

Holding current value

$149,640

Previous $184,000 29.89%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.93 - $4.94 $40,343 - $68,018	13,769 Added 19.52%	84,313 $252,000
Q1 2024 May 15, 2024	SELL	$3.1 - $6.8 $945,853 - $2.07 Million	-305,114 Reduced 81.22%	70,544 $328,000
Q4 2023 Feb 14, 2024	SELL	$2.45 - $4.22 $138,270 - $238,164	-56,437 Reduced 13.06%	375,658 $1.56 Million
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $386,133 - $590,099	-155,699 Reduced 26.49%	432,095 $1.3 Million
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $182,570 - $291,126	-82,239 Reduced 12.27%	587,794 $1.45 Million
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $898,278 - $1.91 Million	401,017 Added 149.07%	670,033 $1.51 Million
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $1.44 Million - $23.7 Million	-661,588 Reduced 71.09%	269,016 $938,000
Q3 2022 Nov 14, 2022	SELL	$18.3 - $37.02 $307,604 - $622,269	-16,809 Reduced 1.77%	930,604 $34.5 Million
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $131,026 - $240,929	7,941 Added 0.85%	947,413 $18 Million
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $10.8 Million - $17.4 Million	645,518 Added 219.6%	939,472 $25.4 Million
Q4 2021 Feb 14, 2022	SELL	$16.93 - $26.82 $1.39 Million - $2.2 Million	-81,898 Reduced 21.79%	293,954 $6.62 Million
Q3 2021 Nov 15, 2021	BUY	$21.86 - $34.77 $281,316 - $447,455	12,869 Added 3.55%	375,852 $9.85 Million
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $10.4 Million - $13.8 Million	352,522 Added 3369.87%	362,983 $11.6 Million
Q1 2021 May 17, 2021	BUY	$31.52 - $39.28 $80,123 - $99,849	2,542 Added 32.1%	10,461 $368,000
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $236,619 - $315,176	7,919 New	7,919 $254,000
Q2 2020 Aug 14, 2020	SELL	$31.59 - $49.98 $10.1 Million - $16 Million	-320,072 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$23.78 - $50.12 $5.7 Million - $12 Million	239,906 Added 299.26%	320,072 $10.9 Million
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $809,676 - $3.78 Million	80,166 New	80,166 $3.13 Million

Others Institutions Holding RLMD

# of Institutions

Shares Held

13.5M

Call Options Held

85.8K

Put Options Held

42.8K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $99.6M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account